CP
GLUE icon

Castleview Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Castleview Partners’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,950
Closed -$70.9K – 689
2024
Q2 		$70.9K Buy
+18,950
New +$96.6K 0.04% 277

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Castleview Partners's GLUE Position: Q3 2024 in Review

Castleview Partners sold out of Monte Rosa Therapeutics (GLUE) in Q3 2024, closing a stake of 18,950 shares — an estimated $70.9K sold.

Castleview Partners first reported a position in GLUE in Q2 2024 and held it in 1 quarter. The position peaked at $70.9K in Q2 2024. 81 funds tracked by Wall St. Rank hold GLUE as of Q3 2024.

  • Castleview Partners reported no remaining Monte Rosa Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Castleview Partners sold 18,950 Monte Rosa Therapeutics shares in Q3 2024, an estimated $70.9K.
  • Castleview Partners first reported a position in Monte Rosa Therapeutics in Q2 2024 and held it in 1 quarter.
  • Castleview Partners's Monte Rosa Therapeutics position peaked at $70.9K in Q2 2024.
  • 81 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2024.

Based on Castleview Partners's 13F filing for Q3 2024, filed 9 Oct 2024.